Merck & Co. management check

MRK · Health Care · Pharmaceuticals · CEO Mr. Davis

Filings as of

64
Management score, ranked 261st of 487 · 28th of 60 in Health Care2 good · 4 to watch · 1 flaggedStrongest: CEO cost · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$158Peers$198

    What $100 became since fiscal 2021

    2532nd
    Detail

    $100 invested at the start of fiscal 2021 grew to $158, against $198 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns20212025

    Pay actually paid $100 value, each on its own scale

    6829th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.37 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.1% of net income

    $20.8m pay · $18.3bn net income, FY2025

    0.1%1%3%10%
    100100th
    Detail

    $20.8m of reported pay in fiscal 2025, against $18.3bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $38.6m sold

    ——
    Detail

    5 insiders sold $38.6m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 2.5bn2025 · 2.5bn

    Diluted shares −0.8% a year; flagged above +2%

    0%10%20%

    Stock pay 1.3% of revenue

    6050th
    Detail

    Diluted shares changed -0.8% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    5 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Mr. Davis, Mr. Frazier

    6038th
    Detail

    CEOs in the pay table: Mr. Davis, Mr. Frazier. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Watch

    Are the books clean?

    An annual report was amended

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 110-K amended
    7015th
    Detail

    No restatements, auditor changes or late filings since 2021. 1 amended annual report.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 8, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$26.2m$52.5m$10020212022202320242025$158$198

Pay tied most to Non-GAAP EPS

Other key measuresRevenueRelative Total Shareholder Return (“R-TSR”)Pre-Tax IncomeNon-GAAP Earnings Per Share (“EPS”)PipelineSustainability

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Davis$20.8m$15.8m$6.9m$158$198$18.3bn
2024Mr. Davis$23.2m$14.7m$9.5m$144$146$17.1bn
2023Mr. Davis$20.3m$26.7m$7.6m$154$134$365.0m
2022Mr. Davis$18.7m$52.5m$8.4m$152$130$14.5bn
2021Mr. Davis, Mr. Frazier$15.2m$14.4m$6.7m$102$122$12.3bn

Insiders and the CEO's stakeSelling

5 insiders sold $38.6m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldRichard R. DeLucaEVP&Pres, Merck Animal Heallth$15.3mNov 12, 2026
  • SoldJennifer ZacharyEVP, General Counsel$10.7mAug 12, 2026
  • SoldDavid Michael WilliamsEVP,Chief Info&Digital Officer$6.8mAug 5, 2026
  • SoldChirfi GuindoEVP, Access, Policy & Comms$3.3mAug 13, 2026

Leadership and governance on file

20222023202420252026Leadership 6Red flags 1Votes 5
All 7 filings

Latest shareholder vote results: May 28, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $45.7bn returned to owners in buybacks and dividends, 73% of net income, and $3.2bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$9.1bn$18.3bn20212022202320242025Shares2.54bn2.54bn2.55bn2.54bn2.51bn
Show the figures
Fiscal year20212022202320242025
Revenue$48.7bn$59.3bn$60.1bn$64.2bn$65.0bn
Net income$12.3bn$14.5bn$365.0m$17.1bn$18.3bn
Stock-based pay$479.0m$541.0m$645.0m$761.0m$820.0m
Buybacks$840.0m$0$1.3bn$1.3bn$5.1bn
Dividends$6.6bn$7.0bn$7.4bn$7.8bn$8.2bn
Diluted shares2538m2542m2547m2541m2507m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.